Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Primaquine phosphate
Drug ID BADD_D01839
Description An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
Indications and Usage For the treatment of malaria.
Marketing Status Prescription
ATC Code P01BA03
DrugBank ID DB01087
KEGG ID D02126
MeSH ID D011319
PubChem ID 6135
TTD Drug ID D0T1LK
NDC Product Code 65392-2502; 0024-1596; 42973-177; 76385-102; 43063-225; 60429-035; 57451-1198; 43063-721; 14096-177; 73309-012; 42291-510; 50742-191
Synonyms Primaquine | Primaquine Phosphate | Phosphate, Primaquine | Primacin | Primaquine Diphosphate | Diphosphate, Primaquine
Chemical Information
Molecular Formula C15H27N3O9P2
CAS Registry Number 63-45-6
SMILES CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2.OP(=O)(O)O.OP(=O)(O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Arrhythmia02.03.02.001--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspepsia07.01.02.001--
Electrocardiogram QT prolonged13.14.05.004--
Haemolytic anaemia01.06.03.002--Not Available
Leukopenia01.02.02.001--Not Available
Methaemoglobinaemia01.05.01.002--
Nausea07.01.07.001--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Vomiting07.01.07.003--
The 1th Page    1    Total 1 Pages